Follow us on Twitter
twitter icon@FreshPatents


Intraperitoneal patents

      

This page is updated frequently with new Intraperitoneal-related patent applications.




 Neo-islets comprising stem and islet cells and treatment of diabetes mellitus therewith patent thumbnailNeo-islets comprising stem and islet cells and treatment of diabetes mellitus therewith
Described are neo-islets comprising: a) dedifferentiated islet cells and mesenchymal and/or adipose stem cells; or b) redifferentiated islet cells and mesenchymal and/or adipose stem cells where the cells have been treated so as to facilitate redifferentiation. Further described herein are methods of generating neo-islets, the methods comprising: culturing a) dedifferentiated islet cells and mesenchymal and/or adipose stem cells; or b) redifferentiated islet cells and mesenchymal and/or adipose stem cells; on a surface that promotes the formation of cell clusters.
Symbiocelltech, Llc


 Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy patent thumbnailComposition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration.
Contrafect Corporation


 Methods for producing high concentration lyophilized pharmaceutical formulations patent thumbnailMethods for producing high concentration lyophilized pharmaceutical formulations
The present invention relates to methods of producing lyophilized pharmaceutical compositions comprising a high concentration of therapeutic protein or antibody prior to lyophilization, wherein the lyophilized formulation can be reconstituted with a diluent in about 15 minutes or less. The invention also relates to the high concentration lyophilized formulations produced by the methods described herein.
Merck Sharp & Dohme Corp.


 Compositions and methods for treating ovarian cancer including preventing the recurrence thereof patent thumbnailCompositions and methods for treating ovarian cancer including preventing the recurrence thereof
A method of treating ovarian cancer (oc) includes administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising vicrostatin and/or a protein substantially similar to vicrostatin. The administration is preferably performed intraperitoneally.
University Of Southern California


 Electromyography with prosthetic or orthotic devices patent thumbnailElectromyography with prosthetic or orthotic devices
Systems, devices and methods for control of a prosthetic or orthotic device (pod) based on electromyography (emg) signals are described. The pod may be a lower or upper limb pod having one or more joints.
Össur Iceland Ehf


 Method and system for producing and delivering airless medical ice slurry to induce hypothemia patent thumbnailMethod and system for producing and delivering airless medical ice slurry to induce hypothemia
The present invention relates to a method and system for producing and delivering sterile, airless, and highly loaded ice slurry for inducing therapeutic hypothermia. The method is capable of producing and delivering ice slurry in a patient to induce hypothermia through internal and external cooling methods such as subcutaneous, intravascular, intraperitoneal, gastrointestinal, and lung methods.

 Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally patent thumbnailMethods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
One aspect of the invention relates to methods of treating cancer in a patient comprising administering intraperitoneally to a patient in need thereof a cancer treating effective amount of a composition comprising a lipid-complexed platinum compound wherein the concentration of the platinum compound of the lipid-complexed platinum compound composition is greater than about 1.2 mg/ml. Another aspect of the invention relates to lipid-complexed platinum compound compositions where the concentration of the platinum compound is greater than about 1.2 mg/ml..
Insmed Incorporated


 Method for inducing artificial ovulation and spawning of fresh-water eels patent thumbnailMethod for inducing artificial ovulation and spawning of fresh-water eels
According to an example, artificial ovulation and spawning of freshwater eels may be induced to promote artificial ovulation without employing intraperitoneal injection, by feeding a feminization-inducing material (e.g., 17β-estradiol) for inducing feminization during a predetermined period into a raising bath in which broodfish are raised and, when an ovulation induction period arrives, adding pituitary extracts of catadromous fish as an artificial ovulation-promoting substance to the bath. Raising water of the raising bath may be prepared by selectively setting fresh water, brackish water and seawater conditions, a feminization-inducing material for inducing complete feminization of broodfish of the freshwater eels is fed to the raising bath, including the raising water under a fresh water condition, and pre-treatment for feminization is performed.
Googol Holdings Co., Ltd


 Medical treatment system and methods using a plurality of fluid lines patent thumbnailMedical treatment system and methods using a plurality of fluid lines
Improvements in fluid volume measurement systems are disclosed for a pneumatically actuated diaphragm pump in general, and a peritoneal dialysis cycler using a pump cassette in particular. Pump fluid volume measurements are based on pressure measurements in a pump control chamber and a reference chamber in a two-chamber model, with different sections of the apparatus being modeled using a combination of adiabatic, isothermal and polytropic processes.

 Method and system providing more accurate fluid temperature monitoring with selectable fluid input and output arragements for body cavity treatments patent thumbnailMethod and system providing more accurate fluid temperature monitoring with selectable fluid input and output arragements for body cavity treatments
Arrangements of components for use in support of a hyperthermic intraperitoneal chemotherapy (hipec) system which conveys fluids from a system to a patient and back to the system in a complete circuit. The described arrangements provide multiple means of rapidly configuring the number of input lines and output lines into and out of the patient.

Medical treatment system and methods using a plurality of fluid lines

Improvements in fluid volume measurement systems are disclosed for a pneumatically actuated diaphragm pump in general, and a peritoneal dialysis cycler using a pump cassette in particular. Pump fluid volume measurements are based on pressure measurements in a pump control chamber and a reference chamber in a two-chamber model, with different sections of the apparatus being modeled using a combination of adiabatic, isothermal and polytropic processes.

Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy

The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration.
Contrafect Corporation

Site 2 insulin analogues

An insulin analogue contains one or more modifications at a distinct protein surface comprising one or more of the residues at position b13, b17, a12, a13, and/or a17. Formulations of the above analogues at successive strengths u-100 to u-1000 in soluble solutions a at least ph value in the range 6.8-8.0 either in the presence of zinc ions at a molar ratio of 2.2-10 zinc ions per six insulin analogue monomers or in the presence of fewer than 1 zinc ions per six insulin analogue monomers.
Case Western Reserve University

Medical treatment system and methods using a plurality of fluid lines

A medical treatment system, such as peritoneal dialysis system, may include control and other features to enhance patient comfort and ease of use. For example, a peritoneal dialysis system may include a control system that can adjust the volume of fluid infused into the peritoneal cavity to prevent the intraperitoneal fluid volume from exceeding a pre-determined amount.
Deka Products Limited Partnership

Use of the pat nonapeptide in the treatment and prevention of neurodegenerative diseases

A pat nonapeptide of formula eaksqggsd can be used to treat or prevent neurodegenerative diseases such as alzheimer's disease, parkinson's disease, huntington's disease and amyotrophic lateral sclerosis. Pharmaceutical compositions containing the pat nonapeptide can be formulated for administration by parenteral route, including the subcutaneous, intraperitoneal, intravenous or intranasal routes..
Orphit

Targeted polymeric inflammation-resolving nanoparticles

Sub-100 micron multimodal nanoparticles have four main components: 1) a target element (peptides, lipids, antibodies, small molecules, etc.) that can selectively bind to cells, tissues, or organs of the body; 2) a diagnostic agent such as a fluorophore or nmr contrast agent that allows visualization of nanoparticles at the site of delivery and/or a therapeutic or prophylactic agent; 3) an outside “stealth” layer that allows the particles to evade recognition by immune system components and increase particle circulation half-life; and 4) a biodegradable polymeric material, forming an inner core which can carry therapeutics and release the payloads at a sustained rate after systemic, intraperitoneal, or mucosal administration. These particles possess excellent stability, high loading efficiency, multiple agent encapsulation, targeting and imaging.
The Trustees Of Columbia University

Methods for reducing fibrosis induced by peritoneal dialysis

The disclosure relates to a method of preventing, inhibiting, or reducing fibrosis, the incidence of fibrosis or the progression of fibrosis associated with peritoneal dialysis, during or after peritoneal is administered. More specifically, the methods relates to using intraperitoneal administration of activated protein c (apc) possessing cytoprotective or anti-inflammatory activity, to reduce the incidence or progression of fibrosis associated with peritoneal dialysis.
Saint Louis University

Pharmaceutical composition containing conventional liposomes and prolonged-circulation liposomes for the treatment of visceral leishmaniasis

The present invention relates to a pharmaceutical composition for treating visceral leishmaniasis, characterized in that it comprises the association of conventional liposomes and prolonged-circulation liposomes with a leishmanicidal-drug delivery system. Said composition may be used in the preparation of a medicinal product for treating leishmaniasis and may be administered intramuscularly, subcutaneously, intraperitoneally or intravenously.
FundaÇao De Amparo A Pesquisa Do Estado De Minas Gerais- Fapemig

Reducing post-operative adhesion formation with intraperitoneal glutamine

intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient.. .
Ade Therapeutics Inc.

Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer

The invention discloses high levels of receptors for clostridium perfringens enterotoxin (cpe) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of cpe is disclosed.
Yale University

Liposome composition for use in peritoneal dialysis

The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the ph within the liposomes differs from the ph in the intraperitoneal cavity and wherein the ph within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes.
Eth Zurich

Composite absorbable/biodegradable rings for controlled drug delivery

A fiber-reinforced composite ring for the controlled release of at least one bioactive agent includes a biocompatible matrix reinforced with absorbable/biodegradable fibers capable of providing the mechanical properties needed for inserting and maintaining the ring in a body cavity for a desired period of time. Such ring system as can be used for the intravaginal, intraperitoneal, and subcutaneous delivery of at least one bioactive agent, including those used as contraceptives, antimicrobial agents, and/or antiviral agents, as well as those for the treatment of cancer..
Poly-med, Inc.

Dipeptide mimetics of ngf and bdnf neurotrophins

The invention relates to compounds having either agonist or antagonist activities for the neurotrophins ngf and bdnf and represented by monomeric or dimeric substituted dipeptides that are analogs of the exposed portions of loop 1 or loop 4 regions of these neurotrophins near or at a beta-turn of the respective loop. N-acylated substituents of these dipeptides are biostereoisomers of the amino acid residues preceding these dipeptide sequences in the neurotrophin primary structure.
Uchrezhdenie Rossiiskoi Akademii Meditsynskikh Nauk Nauchno-issledovatelsky Institut Farmakologii

Line leaf inula flower lactone a and methods for preparing and using the same for treating myocarditis

The compound shows positive therapeutic activity against coxsackie virus and significant dose dependent correlation. The line leaf inula flower lactone a prevents disease in mouse models of experimental autoimmune myocarditis and onset of the process by intraperitoneal injection of a dose of 20 mg/kg/d.

Dye conjugated peptides for fluorescent imaging

The present application discloses compositions and methods of use of peptide targetable constructs for detection, diagnosis and/or imaging of cancer. In preferred embodiments, the targetable construct comprises at least one hapten, at least one fluorescent probe, a chelating moiety and a group iiia metal-18f complex attached to the chelating moiety.
Immunomedics, Inc.

Medicament, method, and drug delivery device for treatment of ovarian cancer

Drug delivery devices, medicaments, and methods are provided for the intraperitoneal treatment of ovarian cancer. An implantable device for drug delivery includes an elongated, flexible device having a housing defining a reservoir that contains a drug in solid or semi-solid form, and configured to be wholly deployed within the peritoneal cavity of a patient and continuously release a therapeutically effective amount of the drug over a period of at least 24 hours.
The General Hospital Corporation

Drug elution for in vivo protection of bio-sensing analytes

A sensor (e.g., an optical sensor) that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing, an analyte indicator covering at least a portion of the sensor housing, and one or more therapeutic agents.
Senseonics, Incorporated

Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme

The invention relates to a method of treating mucopolysaccharidoses using enzyme replacement therapy with chemically modified lysosomal enzymes. More specifically the method relates to administering chemically modified lysosomal enzymes intraperitoneal injection.
Carol Ann Foundation And International Morquio Organization

Multiple emulsion

The invention relates to a multiple emulsion for the application of at least one pharmaceutical or cosmetic active ingredient which has an external water phase w1, an oil phase o dispersed in the external water phase w1 and an internal water phase w2 dispersed in the oil phase o, where, in the internal water phase w2, at least one electrolyte selected from the group of the alkali metal and alkaline earth metal halides and sulphates and at least one hydrophilic active ingredient is provided. In order to achieve a high stability of the emulsion, the invention envisages that the external water phase comprises a hydrophilic emulsifier which is a polymer of ethylene oxide and propylene oxide, and that the oil phase o is formed by triacylglycerides and has a lipophilic emulsifier from the group of dimethicones.

Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers

In one embodiment, the invention provides a new design of nanocarrier compositions that release their therapeutic load specifically at intraperitoneal cancers' site. These nanocarriers are administered intraperitoneally and comprise a plurality of porous nanoparticulates that (a) are loaded with one or more pharmaceutically-active agents alone or in combination with imaging agents thus providing a theranostic value and (b) that are encapsulated by and that support a lipid bilayer which is disrupted upon contact with a reactive oxygen species generated within the environment of the cancer.

Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases

Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.. .

Use of cyclohexanehexol derivatives in the treatment of ocular diseases

The present invention relates to methods of treating ocular diseases in a subject by administering to the subject a therapeutically effective amount of one or more cyclohexanehexyl derivatives, or salts thereof, or a medicament comprising a cyclohexanehexol derivative and a pharmaceutically acceptable carrier. More specifically, the invention provides a medicament comprising at least one cyclohexanehexyl derivative of formula (iii) or (iv) useful in preventing or treating ocular diseases, by modulating the folding, oligomerization or aggregation of amyloid β in ocular cells.

Methods and compositions for treating mammalian nerve tissue injuries

To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injury.

Patient simulation system for medical services or diagnostic machines

A system, method, and apparatus for a patient simulator that interacts with a diagnostic or therapeutic medical device. The system includes a computing device coupled to a patient module.

Block copolymer for intraperitoneal administration containing anti-cancer agent, micelle preparation thereof, and cancer therapeutic agent comprising the micelle preparation as active ingredient

A therapeutic agent as a micelle preparation, comprising a copolymer having a hydrophilic polymeric moiety and a polycarboxylic acid derivative moiety; and an anti-cancer agent bonding to or encapsulated in the copolymer, wherein the micelle preparation may exhibit sustained drug release capability, and enables an extension of a retention time period of the anti-cancer agent in an abdominal cavity, is provided. A superior life-prolonging effect was found in an intraperitoneal administration mouse model compared with a case in which only an encapsulated drug is administered, and thus the present invention was completed accordingly..

Composite absorbable/biodegradable rings for controlled drug delivery

A fiber-reinforced composite ring for the controlled release of at least one bioactive agent includes a biocompatible matrix reinforced with absorbable/biodegradable fibers capable of providing the mechanical properties needed for inserting and maintaining the ring in a body cavity for a desired period of time. Such ring system as can be used for the intravaginal, intraperitoneal, and subcutaneous delivery of at least one bioactive agent, including those used as contraceptives, antimicrobial agents, and/or antiviral agents, as well as those for the treatment of cancer..

Pharmaceutical composition

A pharmaceutical composition for intraperitoneal delivery of an anti-neoplastic agent is provided for treating cancers associated with aberrant mucin expression, preferably ovarian cancer and pancreatic, prostate, metastatic breast, bladder and lung cancers. The composition comprises nanomicelles loaded with the anti-neoplastic agent, and antibodies such as anti-muc16, anti-muc1 or anti-muc4 are conjugated to these nanomicelles.



Intraperitoneal topics:
  • Intraperitoneal
  • Peritoneal
  • Intravenous
  • Sulfonamide
  • Paclitaxel
  • Subcutaneous
  • Dialysis System
  • Medical Treatment
  • Peritoneal Cavity
  • Peritoneal Dialysis
  • Abdominal Cavity
  • Anastomosis
  • Colorectal
  • Wireless Communication Device
  • Hydrogen Sulfide


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Intraperitoneal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Intraperitoneal with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.1455

    file did exist - file did put2063

    3 - 1 - 40